2021-01-03,b'RT @Biotech2050: @semodough At just $4B peak revenues $ACAD would be valued at ~$24B ($150) on a buyout scenario vs $8.5B current market ca\xe2\x80\xa6'
2021-01-03,b'RT @Biotech2050: @semodough At just $4B peak revenues $ACAD would be valued at ~$24B ($150) on a buyout scenario vs $8.5B current market ca\xe2\x80\xa6'
2021-01-03,b'RT @semodough: LR - neuro comments $ACAD Nuplazid: PDP is $500M-$1B but adding DRP&amp;schizophrenia negative symptoms can take this drug to ~$\xe2\x80\xa6'
2021-01-03,b'RT @semodough: LR - neuro comments $ACAD Nuplazid: PDP is $500M-$1B but adding DRP&amp;schizophrenia negative symptoms can take this drug to ~$\xe2\x80\xa6'
2021-01-03,b'@tomlin_ashcroft @semodough The realist will say \xe2\x80\x9cwhat is the cost to care for DRP patients and will there be an improvement in savings and quality of life if $ACAD nuplazid is used?\xe2\x80\x9d. Once the analysis is done and decisions taken nuplazid revenues will hit $10B+'
2021-01-03,b'RT @Biotech2050: @semodough At just $4B peak revenues $ACAD would be valued at ~$24B ($150) on a buyout scenario vs $8.5B current market ca\xe2\x80\xa6'
2021-01-03,b'@semodough At just $4B peak revenues $ACAD would be valued at ~$24B ($150) on a buyout scenario vs $8.5B current market cap. At $10B+ peak revenue the price could go up to $60B+ ($350+ per share!).'
2021-01-03,b'@semodough DRP is a x10 PDP market for $ACAD and the market penetration will be beyond the sub 20% of the PDP market. Augurs well to hit $10B+ at peak if approved. Rightly so they will not venture in EU as the price they will charge will be a fraction of US triggering backlash.'
2021-01-03,b'RT @semodough: LR - neuro comments $ACAD Nuplazid: PDP is $500M-$1B but adding DRP&amp;schizophrenia negative symptoms can take this drug to ~$\xe2\x80\xa6'
2021-01-03,b'RT @semodough: LR - neuro comments $ACAD Nuplazid: PDP is $500M-$1B but adding DRP&amp;schizophrenia negative symptoms can take this drug to ~$\xe2\x80\xa6'
2021-01-03,"b'LR - neuro comments $ACAD Nuplazid: PDP is $500M-$1B but adding DRP&amp;schizophrenia negative symptoms can take this drug to ~$4B\n$ITCI Caplyta: Schizophrenia is $250-500M, but bipolar depression~$1B&amp;adjunctive MDD to ~$2B $AXSM AXS-05 MDD is $500M-$1B,AAD could drive drug to ~$2B\xf0\x9f\x91\x8d'"
2021-01-03,"b'RT @WayoftheMaster7: $ACAD, 3-1 Q BF! 2\xe2\xac\x87\xef\xb8\x8f on the D &amp; W currently! Trading reversals on the D &amp; W until this gets out of the Inside M! 2-1-2\xe2\x80\xa6'"
2021-01-03,"b'$ACAD, 3-1 Q BF! 2\xe2\xac\x87\xef\xb8\x8f on the D &amp; W currently! Trading reversals on the D &amp; W until this gets out of the Inside M! 2-1-2 cont. M\xe2\xac\x86\xef\xb8\x8f &amp; 3-1-2 Q\xe2\xac\x86\xef\xb8\x8f triggers almost simultaneously at $57.34/$57.46! If triggered, will be targeting top of the Q BF! #TheStrat https://t.co/O5ZpBiPfkt'"
2021-01-03,b'$PVDG CEO To Announce Open Market Share Buy Back Program Before Friday\nhttps://t.co/Mv3xmUJu9A\n\n$ACAD $RDFN $TINO $DKS $MAN $AKER $DRE $HAS $SBGI $DUK $LVS $NWL $POTN'
2021-01-02,b'@DavisTrades Happy New Year. $ACAD Thanks!'
2021-01-02,b'RT @Biotech2050: #biopick2021 deadline is today. Come in and participate . Please RT. $SGMO $ZIOP $PGEN $TGTX $BMYRT $BMY $ACAD $IBB $XBI $\xe2\x80\xa6'
2021-01-02,"b'#biopick2021 deadline is today. Come in and participate . Please RT. $SGMO $ZIOP $PGEN $TGTX $BMYRT $BMY $ACAD $IBB $XBI $KPTI $CRMD $ATNM $XLRN ...., $.... https://t.co/YDkAei1mGp'"
2021-01-01,b'RT @Biotech2050: Which company updates are you waiting most from #JPM21 ?\nA. $SGMO $PGEN $ZIOP\nB. $KPTI $TGTX $ACAD \n\nIf other companies in\xe2\x80\xa6'
2021-01-01,b'Zero shares available to short currently in $ACAD.\nhttps://t.co/enknWvO8WZ'
2020-12-31,b'@FallsBedford @lblegend33 Ok I\xe2\x80\x99ll wait! $ACAD'
2020-12-31,"b""2021 Predictions\n\nThe FDA will approve Nuplazid for dementia-related psychosis.\n\n$ACAD will trade at least 50% higher to today's closing price ($53.46) by year's end.\n\nTrofinetide will ace its phase 3 trial in Rett, leading to a quick NDA."""
2020-12-31,"b'$ACAD rose 30% this year, which is stellar considering the pandemic, the missed primary endpoint of the MDD trial, and odd decision of the FDA to grant only a standard review for the DRP sNDA.'"
2020-12-31,b'@lblegend33 Cmon $ACAD you can do it!'
2020-12-31,b'RT @Biotech2050: Good morning America \xf0\x9f\x87\xba\xf0\x9f\x87\xb8 \n\nWhat a fantastic year this has been for biotech. $BMYRT could give us a Happier Ending.\n$TGTX $H\xe2\x80\xa6'
2020-12-31,b'Good morning America \xf0\x9f\x87\xba\xf0\x9f\x87\xb8 \n\nWhat a fantastic year this has been for biotech. $BMYRT could give us a Happier Ending.\n$TGTX $HALO $ACAD $XLRN $PGEN $SGMO my stars of 2020 https://t.co/DMbpSStei4'
2020-12-31,b'$NRZ CEO To Announce Open Market Share Buy Back Program Before Friday\nhttps://t.co/Mv3xmUJu9A\n\n$ACAD $RDFN $TINO $DKS $MAN $AKER $DRE $HAS $SBGI $DUK $LVS $NWL $POTN'
2020-12-30,b'@ToddWilliamson All or nothing. Added $ZIOP recently. They can manufacture overnight CART using MBIL15 and they infused  on compassionate grounds (nearly dead patients) with early efficacy shown. Hopefully ZIOP $PGEN $SGMO will be the stars of 2021. $TGTX $KPTI $ACAD are 2021 buyout candidates'
2020-12-30,b'Which company updates are you waiting most from #JPM21 ?\nA. $SGMO $PGEN $ZIOP\nB. $KPTI $TGTX $ACAD \n\nIf other companies insert name via response to this tweet.'
2020-12-30,b'20 DMA Support today: $FLXN $FUN $SCHZ $TREB $ABCB $FITB $TROX $MYI $TRTN $ISD $ACAD $PTE $MANU $BCO $TRMK $BHE $JPS $MAIN $CVA $AGM ... https://t.co/deOpbNqdR6'
2020-12-30,b'$ACAD definitely going to finish under $47.85  -3.35 % change recently https://t.co/1zSvnNjMxb'
2020-12-29,"b'RT @TomSilver39: Cantor:"" Neuro-Innovator RevGens Rightsizing for COVIDified 4Q20-Enhanced Potential for 2H21 Beat and Raise. High convicti\xe2\x80\xa6'"
2020-12-29,"b'RT @TomSilver39: Cantor:"" Neuro-Innovator RevGens Rightsizing for COVIDified 4Q20-Enhanced Potential for 2H21 Beat and Raise. High convicti\xe2\x80\xa6'"
2020-12-29,"b'Cantor:"" Neuro-Innovator RevGens Rightsizing for COVIDified 4Q20-Enhanced Potential for 2H21 Beat and Raise. High conviction RevGens names going into 2021: $ACAD, $BHVN, $HALO and $ITCI, both for return to what we see as undervalued prospects for post-COVIDified top-line growth.""'"
2020-12-29,b'Acadia Pharma $ACAD target raised by Cantor Fitzgerald from $61 to $70. Stock currently around $53.\n\n$SPY $QQQ $TSLA $AAPL $AMZN $MSFT $BABA $GOOG $NVDA $NIO $FB $FSR $PTON $TDOC $SQ $PENN $DKNG $TWTR $BA $XPEV $PLTR $BYND $MRNA $PFE $LI $SOLO https://t.co/m0BbyM57uD'
2020-12-29,"b""$ACAD\nAnalyst Actions: Cantor Fitzgerald Adjusts ACADIA Pharmaceuticals' Price Target to $70 From $61, Reiterates Overweight Rating"""
2020-12-29,"b'$ACAD Cantor maintains Overweight, raises PT from 61 to 70'"
2020-12-29,b'Acadia price target raised to $70 from $61 at Cantor Fitzgerald\n$ACAD'
2020-12-29,b'$ACAD price movement -3.45 % https://t.co/1zSvnNjMxb'
2020-12-29,b'Stocks to watch Dec. 29 thru Dec. 31 $aceL $mtch $dish $fdx $acad $tsem $azre $apo $cat $pgre $tsLa $nio $brk.a $brk.b $EH EHang and $MCOA  https://t.co/lmcCR9QmPI'
2020-12-28,b'@biostockguru Been there done that. Will not make that same mistake with $ACAD'
2020-12-28,b'RT @askwarrenhq: $SNDD CEO TO Detail Huge Partnership Agreement With Leading US Company As Early As Wednesday\nhttps://t.co/Mv3xmUJu9A\n\n$ACA\xe2\x80\xa6'
2020-12-28,b'@avidresearch Cushioned my losses in $PLTR $MP $ACAD etc... up 1% on 100/30 portfolio.. THAT is how you win long term'
2020-12-28,b'RT @_B_I_O_T_E_C_H_: JPMorgan Looking Ahead to 2021 \xe2\x80\x93 Buyside Survey\n77% expect #Biotech to outperform the broader markets in 2021\n79% surv\xe2\x80\xa6'
2020-12-28,b'RT @_B_I_O_T_E_C_H_: JPMorgan Looking Ahead to 2021 \xe2\x80\x93 Buyside Survey\n77% expect #Biotech to outperform the broader markets in 2021\n79% surv\xe2\x80\xa6'
2020-12-28,b'RT @AreteTrading: $ACAD - has potential but the $55.97 level proves to be hard to close above. Major support goes back to 2016 $51.99. That\xe2\x80\xa6'
2020-12-27,"b""$KODK to be featured on RLTV network's finance show, Money Matters next week\nhttps://t.co/aQqxh927Rv\n\n$ACAD $RDFN $TINO $DKS $MAN $AKER $DRE $HAS $SBGI $DUK $LVS $NWL $POTN"""
2020-12-27,b'$ACAD - has potential but the $55.97 level proves to be hard to close above. Major support goes back to 2016 $51.99. That should hold.  We need to clear the $56 level and pivot from there. Based upon the base and pattern this could move. $80 target. https://t.co/GsSGXAsc7l'
2020-12-27,b'@AreteTrading $ACAD $IONS'
2020-12-27,b'@Nomadbullstreet @Biotech_SD Long $AUPH but love $ACAD'
2020-12-27,"b'RT @semodough: $ACAD key catalysts\nNuplazid- April 3, 2021- FDA has set a PDUFA date for the potential approval\nof Nuplazid in dementia-rel\xe2\x80\xa6'"
2020-12-27,"b'RT @semodough: $ACAD key catalysts\nNuplazid- April 3, 2021- FDA has set a PDUFA date for the potential approval\nof Nuplazid in dementia-rel\xe2\x80\xa6'"
2020-12-27,"b'RT @semodough: JEFF 2022Top M&amp;A ideas include: $ACAD, $ALLK $TGTX $ALXO, $IOVA, $CNST,   Honestly not sure what my reaction will be if $TGT\xe2\x80\xa6'"
2020-12-27,"b""#2021picks $IDRA $RGLS $ITRM $ALKS $OCUL $SGMO $VSTM $SMMT $INVA $ACAD #2021stockpicks ! Known all of them that's why but I bought after a a longggg research is the key !! https://t.co/GSlfBA5rL9"""
2020-12-27,"b'RT @ForTheRecord01: $ACAD Short interest fell over 800,000 shares in early Dec. It has fallen over 2 million shares in the last three month\xe2\x80\xa6'"
2020-12-27,"b'$ACAD Short interest fell over 800,000 shares in early Dec. It has fallen over 2 million shares in the last three months.\n\nSI is now at a 5-year low. Short-sellers likely only see good news on the horizon along with a punishingly rising stock price.\n\nhttps://t.co/OypuCp3bwF'"
2020-12-27,b'$SNDD CEO TO Detail Huge Partnership Agreement With Leading US Company As Early As Wednesday\nhttps://t.co/Mv3xmUJu9A\n\n$ACAD $RDFN $TINO $DKS $MAN $AKER $DRE $HAS $SBGI $DUK $LVS $NWL $POTN'
2020-12-27,"b'RT @semodough: $ACAD key catalysts\nNuplazid- April 3, 2021- FDA has set a PDUFA date for the potential approval\nof Nuplazid in dementia-rel\xe2\x80\xa6'"
2020-12-27,"b'$ACAD key catalysts\nNuplazid- April 3, 2021- FDA has set a PDUFA date for the potential approval\nof Nuplazid in dementia-related psychosis (DRP).\nTrofinetide-2H21- Phase 3 data in Rett Syndrome are expected in 2H21. https://t.co/EMjbeplmNa'"
2021-01-07,b'$RDGL This could be the next big pharma buyout. FDA update by 01-16-21. $AYTU $AIM $NVAX $INO $XSPA $AIKI $SNY $SIGA $LEG $GILD $AZN $ACB $GNFT $ENZC $JNJ $GERN $ACAD $JAZZ $BLUE $KITE $AMGN $RDUS https://t.co/nyFJbXc76W'
2021-01-07,"b'RT @TomSilver39: Mizuho 2021 SMID Biotech Outlook: Top picks in 2021 which are $SRPT, $CNCE, $BLUE, and $FGEN. Biopharma Outlook; Top Picks\xe2\x80\xa6'"
2021-01-07,"b'RT @TomSilver39: Mizuho 2021 SMID Biotech Outlook: Top picks in 2021 which are $SRPT, $CNCE, $BLUE, and $FGEN. Biopharma Outlook; Top Picks\xe2\x80\xa6'"
2021-01-07,b'RT @Biotech2050: #JPM21 #JPMorgan $BMY $TGTX $XLRN $KPTI $PGEN $ZIOP $ACAD $HALO $SGMO \n\nWhich other companies\xe2\x80\x99 presentations are you looki\xe2\x80\xa6'
2021-01-07,"b'RT @TomSilver39: Mizuho 2021 SMID Biotech Outlook: Top picks in 2021 which are $SRPT, $CNCE, $BLUE, and $FGEN. Biopharma Outlook; Top Picks\xe2\x80\xa6'"
2021-01-07,b'#JPM21 #JPMorgan $BMY $TGTX $XLRN $KPTI $PGEN $ZIOP $ACAD $HALO $SGMO \n\nWhich other companies\xe2\x80\x99 presentations are you looking forward too? Will a buyout be announced just before the event? https://t.co/LFwa2F4hGF'
2021-01-07,"b'RT @TomSilver39: Mizuho 2021 SMID Biotech Outlook: Top picks in 2021 which are $SRPT, $CNCE, $BLUE, and $FGEN. Biopharma Outlook; Top Picks\xe2\x80\xa6'"
2021-01-07,"b'Mizuho 2021 SMID Biotech Outlook: Top picks in 2021 which are $SRPT, $CNCE, $BLUE, and $FGEN. Biopharma Outlook; Top Picks are : $ABBV, $ACAD, $ALKS, $KRTX and $AXSM .""'"
2021-01-07,b'$ISR All top managers added 10 to 100% shares in late 2020! HUGE!\nhttps://t.co/eIlnz4JVNb\n\n$MU $TWTR $FB $BCRX $SPY $CLDR $GEMP $MVIS $RVLT $ISR $TSLA $AAPL $WMT $UVXY $TZA $MNKD $ZM $AUPH $ACAD $APDN $FCEL $SIRI $MRNA $FB $OPGN $SIF $CLSD $APT $CYCN $CODX $CLSD $INO $AYTU $IDEX https://t.co/dKmzB5QJUP'
2021-01-07,b'20 DMA Support today: $MRCY $PAGS $LDP $INVH $EQD $CMLS $ACAD $LYV $ENBL $NG $JBLU $NTEC $QGEN $ETY $FMX $ADV $MD $UTL $UTSI $BSJL ... https://t.co/deOpbNqdR6'
2021-01-07,"b'Long $ACAD ACADIA Pharmaceutricals @ $54.8. Pivot $54, ST-Support $51 https://t.co/XiA33zTfNv'"
2021-01-07,"b'RT @semodough: Mizuho 2021 Biopharma Outlook; Top Picks are $ABBV, $ACAD, $ALKS, $KRTX $AXSM'"
2021-01-07,"b'RT @semodough: Mizuho 2021 Biopharma Outlook; Top Picks are $ABBV, $ACAD, $ALKS, $KRTX $AXSM'"
2021-01-07,"b'RT @semodough: Mizuho 2021 Biopharma Outlook; Top Picks are $ABBV, $ACAD, $ALKS, $KRTX $AXSM'"
2021-01-07,"b'RT @semodough: Mizuho 2021 Biopharma Outlook; Top Picks are $ABBV, $ACAD, $ALKS, $KRTX $AXSM'"
2021-01-07,"b'Mizuho 2021 Biopharma Outlook; Top Picks are $ABBV, $ACAD, $ALKS, $KRTX $AXSM'"
2021-01-07,b'$ACAD auction is now open. 3.38 % change recently https://t.co/5rGAHkRyvb'
2021-01-07,b'$ISR All top managers added 10 to 100% shares in late 2020! HUGE!\nhttps://t.co/eIlnz4JVNb\n\n$MU $TWTR $FB $BCRX $SPY $CLDR $GEMP $MVIS $RVLT $ISR $TSLA $AAPL $WMT $UVXY $TZA $MNKD $ZM $AUPH $ACAD $APDN $FCEL $SIRI $MRNA $FB $OPGN $SIF $CLSD $APT $CYCN $CODX $CLSD $INO $AYTU $IDEX'
2021-01-07,b'$ACAD  new alert at https://t.co/A7qrDarJHY  #stocks #daytrading  #NYSE #NASDAQ #market 931'
2021-01-06,b'$ISR MASSIVE FDA NEWS gonna break $3\xf0\x9f\x92\xb8\xf0\x9f\x93\x88\n\n$AMRH $UAVS $TRXC $NGD $FOLD $BDR $TOPS $CUR $BYFC $STNE $SNBR $LJPC $GLUU $TWTR $XLNX $LABU $NDRA $CPG $ASGN $TRVG $KN $TAL $NVT $CVI $MLNX $IP $TKC $ZIOP $ACAD $PTEN $TRTC $DRYS $FNMA $GNUS $LK $MGM $ZOM $SHIP $RIOT $MARA $ATNM $PFE https://t.co/vhD9RC80mm'
2021-01-06,"b'$ACAD Again another nearly 600,000 shares trades Exactly at 4PM on an Up Day.....Clearly someone is accumulating...If that was a sell order with no bids the stock would have dropped 5 points to accommodate....Time for an Update.... https://t.co/3XbbiHrBLk https://t.co/QLtaU6jyYW'"
2021-01-06,"b'$ACAD ACADIA Pharmaceuticals Receives Average Recommendation of ""Buy"" from Analysts | $$60.81 Average PT https://t.co/NKb5pRLCDo https://t.co/StcSQX8Sex'"
2021-01-06,b'Rose Above 50 DMA today: $ACAD $WPC ... https://t.co/qwiJH6vr1O'
2021-01-06,b'$ISR MASSIVE FDA NEWS gonna break $3\xf0\x9f\x92\xb8\xf0\x9f\x93\x88\n\n$AMRH $UAVS $TRXC $NGD $FOLD $BDR $TOPS $CUR $BYFC $STNE $SNBR $LJPC $GLUU $TWTR $XLNX $LABU $NDRA $CPG $ASGN $TRVG $KN $TAL $NVT $CVI $MLNX $IP $TKC $ZIOP $ACAD $PTEN $TRTC $DRYS $FNMA $GNUS $LK $MGM $ZOM $SHIP $RIOT $MARA $ATNM $PFE https://t.co/g8jBHLoiyh'
2021-01-06,b'$ACAD  new alert at https://t.co/A7qrDarJHY  #stocks #daytrading  #NYSE #NASDAQ #market 465'
2021-01-06,"b'RT @Biotech2050: @Clive_Ballard Video: Clive Ballard, MD: Pimavanserin In Patients With Dementia-Related Psychosis\nhttps://t.co/hq9SlLqK6S\xe2\x80\xa6'"
2021-01-06,b'@ForTheRecord01 More importantly pimavanserin is endorsed by a top key opinion leader in the field of #dementia #Alzheimers #Parkinsons #hallucinations #cns #psychosis\n\nAugurs well for $ACAD https://t.co/sBTnVS3wf7'
2021-01-06,b'RT @ForTheRecord01: $ACAD The FDA is 6.5 months into its review of Nuplazid for DRP. Approval is just a formality now given the clinical sc\xe2\x80\xa6'
2021-01-06,b'$KPTI $ACAD $ARCT $BTAI $TWST some biotechs that i m studying. Please share or tag me on any related info if u know if any.'
